img

Global Specific Antiviral Drugs for COVID-19 Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Latest Trends

Publisher : MRA | Format : PDF

Global Specific Antiviral Drugs for COVID-19 Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application

Specific Antiviral Drugs for COVID-19 report published by MRA Research reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2023. Global Specific Antiviral Drugs for COVID-19 market is projected to reach US$ million in 2033, increasing from US$ million in 2023, with the CAGR of % during the period of 2023 to 2033. Demand from Mild Symptom Patient and Critically Ill Patient are the major drivers for the industry.
The global pharmaceutical market is 1475 billion USD in 2023, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2023. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2023. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2023) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Specific Antiviral Drugs for COVID-19 market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group
Segment by Type
Tablet
Injection

Segment by Application


Mild Symptom Patient
Critically Ill Patient
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Specific Antiviral Drugs for COVID-19 market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Specific Antiviral Drugs for COVID-19 introduction, etc. Specific Antiviral Drugs for COVID-19 Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRA Research’s Conclusions of Specific Antiviral Drugs for COVID-19 market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRA Research.

Table of Content

1 Market Overview of Specific Antiviral Drugs for COVID-19
1.1 Specific Antiviral Drugs for COVID-19 Market Overview
1.1.1 Specific Antiviral Drugs for COVID-19 Product Scope
1.1.2 Specific Antiviral Drugs for COVID-19 Market Status and Outlook
1.2 Global Specific Antiviral Drugs for COVID-19 Market Size Overview by Region 2018 VS 2023 VS 2033
1.3 Global Specific Antiviral Drugs for COVID-19 Market Size by Region (2018-2033)
1.4 Global Specific Antiviral Drugs for COVID-19 Historic Market Size by Region (2018-2023)
1.5 Global Specific Antiviral Drugs for COVID-19 Market Size Forecast by Region (2024-2033)
1.6 Key Regions, Specific Antiviral Drugs for COVID-19 Market Size (2018-2033)
1.6.1 North America Specific Antiviral Drugs for COVID-19 Market Size (2018-2033)
1.6.2 Europe Specific Antiviral Drugs for COVID-19 Market Size (2018-2033)
1.6.3 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size (2018-2033)
1.6.4 Latin America Specific Antiviral Drugs for COVID-19 Market Size (2018-2033)
1.6.5 Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size (2018-2033)
2 Specific Antiviral Drugs for COVID-19 Market by Type
2.1 Introduction
2.1.1 Tablet
2.1.2 Injection
2.2 Global Specific Antiviral Drugs for COVID-19 Market Size by Type: 2018 VS 2023 VS 2033
2.2.1 Global Specific Antiviral Drugs for COVID-19 Historic Market Size by Type (2018-2023)
2.2.2 Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Type (2024-2033)
2.3 Key Regions Market Size by Type
2.3.1 North America Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Type (2018-2033)
2.3.2 Europe Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Type (2018-2033)
2.3.3 Asia-Pacific Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Type (2018-2033)
2.3.4 Latin America Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Type (2018-2033)
2.3.5 Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Type (2018-2033)
3 Specific Antiviral Drugs for COVID-19 Market Overview by Application
3.1 Introduction
3.1.1 Mild Symptom Patient
3.1.2 Critically Ill Patient
3.2 Global Specific Antiviral Drugs for COVID-19 Market Size by Application: 2018 VS 2023 VS 2033
3.2.1 Global Specific Antiviral Drugs for COVID-19 Historic Market Size by Application (2018-2023)
3.2.2 Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Application (2024-2033)
3.3 Key Regions Market Size by Application
3.3.1 North America Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Application (2018-2033)
3.3.2 Europe Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Application (2018-2033)
3.3.3 Asia-Pacific Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Application (2018-2033)
3.3.4 Latin America Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Application (2018-2033)
3.3.5 Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Breakdown by Application (2018-2033)
4 Specific Antiviral Drugs for COVID-19 Competition Analysis by Players
4.1 Global Specific Antiviral Drugs for COVID-19 Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Specific Antiviral Drugs for COVID-19 as of 2023)
4.3 Date of Key Players Enter into Specific Antiviral Drugs for COVID-19 Market
4.4 Global Top Players Specific Antiviral Drugs for COVID-19 Headquarters and Area Served
4.5 Key Players Specific Antiviral Drugs for COVID-19 Product Solution and Service
4.6 Competitive Status
4.6.1 Specific Antiviral Drugs for COVID-19 Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Sanofi
5.1.1 Sanofi Profile
5.1.2 Sanofi Main Business
5.1.3 Sanofi Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.1.4 Sanofi Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.1.5 Sanofi Recent Developments
5.2 Novartis
5.2.1 Novartis Profile
5.2.2 Novartis Main Business
5.2.3 Novartis Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.2.4 Novartis Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.2.5 Novartis Recent Developments
5.3 Shanghai Zhongxisanwei
5.3.1 Shanghai Zhongxisanwei Profile
5.3.2 Shanghai Zhongxisanwei Main Business
5.3.3 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.3.4 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.3.5 Teva Recent Developments
5.4 Teva
5.4.1 Teva Profile
5.4.2 Teva Main Business
5.4.3 Teva Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.4.4 Teva Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.4.5 Teva Recent Developments
5.5 Zydus Cadila
5.5.1 Zydus Cadila Profile
5.5.2 Zydus Cadila Main Business
5.5.3 Zydus Cadila Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.5.4 Zydus Cadila Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.5.5 Zydus Cadila Recent Developments
5.6 Mylan
5.6.1 Mylan Profile
5.6.2 Mylan Main Business
5.6.3 Mylan Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.6.4 Mylan Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.6.5 Mylan Recent Developments
5.7 Apotex
5.7.1 Apotex Profile
5.7.2 Apotex Main Business
5.7.3 Apotex Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.7.4 Apotex Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.7.5 Apotex Recent Developments
5.8 Advanz Pharma
5.8.1 Advanz Pharma Profile
5.8.2 Advanz Pharma Main Business
5.8.3 Advanz Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.8.4 Advanz Pharma Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.8.5 Advanz Pharma Recent Developments
5.9 Sun Pharma
5.9.1 Sun Pharma Profile
5.9.2 Sun Pharma Main Business
5.9.3 Sun Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.9.4 Sun Pharma Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.9.5 Sun Pharma Recent Developments
5.10 Kyung Poong
5.10.1 Kyung Poong Profile
5.10.2 Kyung Poong Main Business
5.10.3 Kyung Poong Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.10.4 Kyung Poong Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.10.5 Kyung Poong Recent Developments
5.11 Ipca Laboratories
5.11.1 Ipca Laboratories Profile
5.11.2 Ipca Laboratories Main Business
5.11.3 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.11.4 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.11.5 Ipca Laboratories Recent Developments
5.12 Hanlim Pharmaceutical
5.12.1 Hanlim Pharmaceutical Profile
5.12.2 Hanlim Pharmaceutical Main Business
5.12.3 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.12.4 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.12.5 Hanlim Pharmaceutical Recent Developments
5.13 Bristol Laboratories
5.13.1 Bristol Laboratories Profile
5.13.2 Bristol Laboratories Main Business
5.13.3 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.13.4 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.13.5 Bristol Laboratories Recent Developments
5.14 Bayer
5.14.1 Bayer Profile
5.14.2 Bayer Main Business
5.14.3 Bayer Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.14.4 Bayer Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.14.5 Bayer Recent Developments
5.15 Rising Pharmaceutical
5.15.1 Rising Pharmaceutical Profile
5.15.2 Rising Pharmaceutical Main Business
5.15.3 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.15.4 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.15.5 Rising Pharmaceutical Recent Developments
5.16 Shanghai Pharma
5.16.1 Shanghai Pharma Profile
5.16.2 Shanghai Pharma Main Business
5.16.3 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.16.4 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.16.5 Shanghai Pharma Recent Developments
5.17 Sichuan Sunny Hope
5.17.1 Sichuan Sunny Hope Profile
5.17.2 Sichuan Sunny Hope Main Business
5.17.3 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.17.4 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.17.5 Sichuan Sunny Hope Recent Developments
5.18 Guangzhou Baiyunshan Guanghua Pharmaceutical
5.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Profile
5.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Main Business
5.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.18.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments
5.19 CSPC Group
5.19.1 CSPC Group Profile
5.19.2 CSPC Group Main Business
5.19.3 CSPC Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.19.4 CSPC Group Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.19.5 CSPC Group Recent Developments
5.20 KPC Group
5.20.1 KPC Group Profile
5.20.2 KPC Group Main Business
5.20.3 KPC Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.20.4 KPC Group Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.20.5 KPC Group Recent Developments
5.21 Jinghua Pharmaceutical Group
5.21.1 Jinghua Pharmaceutical Group Profile
5.21.2 Jinghua Pharmaceutical Group Main Business
5.21.3 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.21.4 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.21.5 Jinghua Pharmaceutical Group Recent Developments
5.22 Zhongsheng Pharma
5.22.1 Zhongsheng Pharma Profile
5.22.2 Zhongsheng Pharma Main Business
5.22.3 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.22.4 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.22.5 Zhongsheng Pharma Recent Developments
5.23 North China Pharmaceutical Group
5.23.1 North China Pharmaceutical Group Profile
5.23.2 North China Pharmaceutical Group Main Business
5.23.3 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
5.23.4 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) & (2018-2023)
5.23.5 North China Pharmaceutical Group Recent Developments
6 North America
6.1 North America Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2033)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2033)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Region (2018-2033)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2033)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2033)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Specific Antiviral Drugs for COVID-19 Market Dynamics
11.1 Specific Antiviral Drugs for COVID-19 Industry Trends
11.2 Specific Antiviral Drugs for COVID-19 Market Drivers
11.3 Specific Antiviral Drugs for COVID-19 Market Challenges
11.4 Specific Antiviral Drugs for COVID-19 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Specific Antiviral Drugs for COVID-19 Market Size (US$ Million) Comparison by Region 2018 VS 2023 VS 2033
Table 2. Global Specific Antiviral Drugs for COVID-19 Market Size by Region (2018-2023) & (US$ Million)
Table 3. Global Specific Antiviral Drugs for COVID-19 Market Size Share by Region (2018-2023)
Table 4. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 5. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size Share by Region (2024-2033)
Table 6. Global Specific Antiviral Drugs for COVID-19 Market Size (US$ Million) by Type: 2018 VS 2023 VS 2033
Table 7. Global Specific Antiviral Drugs for COVID-19 Market Size by Type (2018-2023) & (US$ Million)
Table 8. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2023)
Table 9. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 10. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2024-2033)
Table 11. North America Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 12. North America Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 13. Europe Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 14. Europe Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 15. Asia-Pacific Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 16. Asia-Pacific Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 17. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 18. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 19. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Type (2018-2023) & (US$ Million)
Table 20. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Type (2024-2033) & (US$ Million)
Table 21. Global Specific Antiviral Drugs for COVID-19 Market Size (US$ Million) by Application: 2018 VS 2023 VS 2033
Table 22. Global Specific Antiviral Drugs for COVID-19 Market Size by Application (2018-2023) & (US$ Million)
Table 23. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2023)
Table 24. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 25. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2024-2033)
Table 26. North America Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 27. North America Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 28. Europe Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 29. Europe Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 30. Asia-Pacific Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 31. Asia-Pacific Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 32. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 33. Latin America Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 34. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Application (2018-2023) & (US$ Million)
Table 35. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue by Application (2024-2033) & (US$ Million)
Table 36. Global Specific Antiviral Drugs for COVID-19 Revenue (US$ Million) by Players (2018-2023)
Table 37. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Players (2018-2023)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Specific Antiviral Drugs for COVID-19 as of 2023)
Table 39. Date of Key Players Enter into Specific Antiviral Drugs for COVID-19 Market
Table 40. Global Specific Antiviral Drugs for COVID-19 Key Players Headquarters and Area Served
Table 41. Specific Antiviral Drugs for COVID-19 Product Solution and Service
Table 42. Global Specific Antiviral Drugs for COVID-19 Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. Sanofi Basic Information List
Table 45. Sanofi Description and Business Overview
Table 46. Sanofi Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 47. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Sanofi (2018-2023)
Table 48. Sanofi Recent Developments
Table 49. Novartis Basic Information List
Table 50. Novartis Description and Business Overview
Table 51. Novartis Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 52. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Novartis (2018-2023)
Table 53. Novartis Recent Developments
Table 54. Shanghai Zhongxisanwei Basic Information List
Table 55. Shanghai Zhongxisanwei Description and Business Overview
Table 56. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 57. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Shanghai Zhongxisanwei (2018-2023)
Table 58. Shanghai Zhongxisanwei Recent Developments
Table 59. Teva Basic Information List
Table 60. Teva Description and Business Overview
Table 61. Teva Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 62. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Teva (2018-2023)
Table 63. Teva Recent Developments
Table 64. Zydus Cadila Basic Information List
Table 65. Zydus Cadila Description and Business Overview
Table 66. Zydus Cadila Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 67. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Zydus Cadila (2018-2023)
Table 68. Zydus Cadila Recent Developments
Table 69. Mylan Basic Information List
Table 70. Mylan Description and Business Overview
Table 71. Mylan Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 72. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Mylan (2018-2023)
Table 73. Mylan Recent Developments
Table 74. Apotex Basic Information List
Table 75. Apotex Description and Business Overview
Table 76. Apotex Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 77. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Apotex (2018-2023)
Table 78. Apotex Recent Developments
Table 79. Advanz Pharma Basic Information List
Table 80. Advanz Pharma Description and Business Overview
Table 81. Advanz Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 82. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Advanz Pharma (2018-2023)
Table 83. Advanz Pharma Recent Developments
Table 84. Sun Pharma Basic Information List
Table 85. Sun Pharma Description and Business Overview
Table 86. Sun Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 87. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Sun Pharma (2018-2023)
Table 88. Sun Pharma Recent Developments
Table 89. Kyung Poong Basic Information List
Table 90. Kyung Poong Description and Business Overview
Table 91. Kyung Poong Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 92. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Kyung Poong (2018-2023)
Table 93. Kyung Poong Recent Developments
Table 94. Ipca Laboratories Basic Information List
Table 95. Ipca Laboratories Description and Business Overview
Table 96. Ipca Laboratories Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 97. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Ipca Laboratories (2018-2023)
Table 98. Ipca Laboratories Recent Developments
Table 99. Hanlim Pharmaceutical Basic Information List
Table 100. Hanlim Pharmaceutical Description and Business Overview
Table 101. Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 102. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Hanlim Pharmaceutical (2018-2023)
Table 103. Hanlim Pharmaceutical Recent Developments
Table 104. Bristol Laboratories Basic Information List
Table 105. Bristol Laboratories Description and Business Overview
Table 106. Bristol Laboratories Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 107. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Bristol Laboratories (2018-2023)
Table 108. Bristol Laboratories Recent Developments
Table 109. Bayer Basic Information List
Table 110. Bayer Description and Business Overview
Table 111. Bayer Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 112. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Bayer (2018-2023)
Table 113. Bayer Recent Developments
Table 114. Rising Pharmaceutical Basic Information List
Table 115. Rising Pharmaceutical Description and Business Overview
Table 116. Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 117. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Rising Pharmaceutical (2018-2023)
Table 118. Rising Pharmaceutical Recent Developments
Table 119. Shanghai Pharma Basic Information List
Table 120. Shanghai Pharma Description and Business Overview
Table 121. Shanghai Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 122. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Shanghai Pharma (2018-2023)
Table 123. Shanghai Pharma Recent Developments
Table 124. Sichuan Sunny Hope Basic Information List
Table 125. Sichuan Sunny Hope Description and Business Overview
Table 126. Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 127. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Sichuan Sunny Hope (2018-2023)
Table 128. Sichuan Sunny Hope Recent Developments
Table 129. Guangzhou Baiyunshan Guanghua Pharmaceutical Basic Information List
Table 130. Guangzhou Baiyunshan Guanghua Pharmaceutical Description and Business Overview
Table 131. Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 132. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Guangzhou Baiyunshan Guanghua Pharmaceutical (2018-2023)
Table 133. Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments
Table 134. CSPC Group Basic Information List
Table 135. CSPC Group Description and Business Overview
Table 136. CSPC Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 137. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of CSPC Group (2018-2023)
Table 138. CSPC Group Recent Developments
Table 139. KPC Group Basic Information List
Table 140. KPC Group Description and Business Overview
Table 141. KPC Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 142. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of KPC Group (2018-2023)
Table 143. KPC Group Recent Developments
Table 144. Jinghua Pharmaceutical Group Basic Information List
Table 145. Jinghua Pharmaceutical Group Description and Business Overview
Table 146. Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 147. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Jinghua Pharmaceutical Group (2018-2023)
Table 148. Jinghua Pharmaceutical Group Recent Developments
Table 149. Zhongsheng Pharma Basic Information List
Table 150. Zhongsheng Pharma Description and Business Overview
Table 151. Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 152. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Zhongsheng Pharma (2018-2023)
Table 153. Zhongsheng Pharma Recent Developments
Table 154. North China Pharmaceutical Group Basic Information List
Table 155. North China Pharmaceutical Group Description and Business Overview
Table 156. North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 157. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of North China Pharmaceutical Group (2018-2023)
Table 158. North China Pharmaceutical Group Recent Developments
Table 159. North America Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023) & (US$ Million)
Table 160. North America Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2033) & (US$ Million)
Table 161. Europe Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023) & (US$ Million)
Table 162. Europe Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2033) & (US$ Million)
Table 163. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 164. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Region (2018-2023) & (US$ Million)
Table 165. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size by Region (2024-2033) & (US$ Million)
Table 166. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Share by Region (2018-2023)
Table 167. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Share by Region (2024-2033)
Table 168. Latin America Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 169. Latin America Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023) & (US$ Million)
Table 170. Latin America Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2033) & (US$ Million)
Table 171. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2023 VS 2033
Table 172. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size by Country (2018-2023) & (US$ Million)
Table 173. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size by Country (2024-2033) & (US$ Million)
Table 174. Specific Antiviral Drugs for COVID-19 Market Trends
Table 175. Specific Antiviral Drugs for COVID-19 Market Drivers
Table 176. Specific Antiviral Drugs for COVID-19 Market Challenges
Table 177. Specific Antiviral Drugs for COVID-19 Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Specific Antiviral Drugs for COVID-19 Market Size Year-over-Year 2018-2033 & (US$ Million)
Figure 2. Global Specific Antiviral Drugs for COVID-19 Market Size (US$ Million), 2018 VS 2023 VS 2033
Figure 3. Global Specific Antiviral Drugs for COVID-19 Market Share by Regions: 2023 VS 2033
Figure 4. Global Specific Antiviral Drugs for COVID-19 Forecasted Market Size Share by Region (2024-2033)
Figure 5. North America Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 6. Europe Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 7. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 8. Latin America Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 9. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 10. Product Picture of Tablet
Figure 11. Global Tablet Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 12. Product Picture of Injection
Figure 13. Global Injection Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 14. Global Specific Antiviral Drugs for COVID-19 Market Size Share by Type: 2023 & 2033
Figure 15. North America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 16. Europe Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 17. Asia-Pacific Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 18. Latin America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 19. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Market Share by Type (2018-2033)
Figure 20. Mild Symptom Patient Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 21. Critically Ill Patient Market Size (US$ Million) & YoY Growth (2018-2033)
Figure 22. Global Specific Antiviral Drugs for COVID-19 Market Size Share by Application: 2023 & 2033
Figure 23. North America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 24. Europe Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 25. Asia-Pacific Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 26. Latin America Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 27. Middle East and Africa Specific Antiviral Drugs for COVID-19 Revenue Market Share by Application (2018-2033)
Figure 28. Specific Antiviral Drugs for COVID-19 Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2023
Figure 29. Global Top 5 and Top 10 Players Specific Antiviral Drugs for COVID-19 Market Share in 2023
Figure 30. North America Specific Antiviral Drugs for COVID-19 Market Share by Country (2018-2033)
Figure 31. United States Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 32. Canada Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 33. Germany Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 34. France Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 35. U.K. Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 36. Italy Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 37. Russia Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 38. Nordic Countries Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 39. Asia-Pacific Specific Antiviral Drugs for COVID-19 Market Share by Region (2018-2033)
Figure 40. China Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 41. Japan Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 42. South Korea Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 43. Southeast Asia Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 44. India Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 45. Australia Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 46. Latin America Specific Antiviral Drugs for COVID-19 Market Share by Country (2018-2033)
Figure 47. Mexico Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 48. Brazil Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 49. Middle East & Africa Specific Antiviral Drugs for COVID-19 Market Share by Country (2018-2033)
Figure 50. Turkey Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 51. Saudi Arabia Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 52. UAE Specific Antiviral Drugs for COVID-19 Market Size (2018-2033) & (US$ Million)
Figure 53. Bottom-up and Top-down Approaches for This Report